Lung cancer

Non-small cell lung cancer
#Gene therapy #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Non-viral gene therapy shows early efficacy in lung cancer

Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC). The data will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. Developed by… Read More

#Cancer Research #News

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

Lungs
#Ariceum Therapeutics #Lung cancer #Murdoch University Health Center #Radiopharmaceuticals #Small cell lung cancer #Theranostics

First patient dosed in Phase Ib study in small cell lung cancer 

Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the Murdoch University Health Center in Perth, Australia.  Ariceum has… Read More

#News

#Cancer drug targets #Cancer research #Cancer vaccine #Immunotherapy #Lung cancer #Oncology

World Lung Cancer Day: Five drug discovery breakthroughs

This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More

#Cancer Research #News #Trending News

T cells attacking cancer
#allogeneic cell therapies #Cancer research #Cancer Research UK #Lineage Cell Therapeutics #Lung cancer #Oncology

Topline results support allogeneic dendritic cell vaccine in lung cancer

Lineage Cell Therapeutics and Cancer Research UK have announced encouraging primary and secondary endpoint results from their clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated… Read More

#Cancer Research #News

Lung cancer
#Cancer research #Immunotherapy #Lung cancer #Oncology #Roche #University College London

Immunotherapy improves lung cancer long-term survival

A global study, led by University College London (UCL) and University College London Hospitals (UCLH) and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients, when compared to single-agent chemotherapy. For… Read More

#Cancer Research #News

Stock market
#AstraZeneca #Business #Cancer research #Lung cancer #Oncology #Trial data

AstraZeneca stock value falls by 8%

Shares in AstraZeneca fell by 6% on July 3 when the company published the first results from its Phase III trial for datopotamab deruxtecan (Dato-DXd) and continued to fall throughout the day, though there was some recovery on July 4. It was reported that the therapy demonstrated statistically significant improvement… Read More

#Business & Investment #News #Trending News

Non-small cell lung cancer
#American Society of Clinical Oncology #ASCO #AstraZeneca #Cancer research #Lung cancer #Oncology #Phase III trial

Lung cancer pill reduced risk of death by more than half

Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor… Read More

#Cancer Research #News #Trending News

Clinical research
#AACR #Cancer research #Funding #Johnson & Johnson #Lung cancer

AACR START Grant offers industry and academia experience

Postdoctoral and clinical fellows are invited to apply for the AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grant by June 21, 2023. This three-year, $225,000 grant will provide the opportunity for training and research in both academia and industry,… Read More

#News

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

Podcast: This week’s drug discovery highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Each of our top five stories this week exemplify the scientific curiosity that fuels the drug… Read More

#News

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

This week in drug discovery (24-28 April)

News round-up for 24-28 April by DDW Digital Content Editor Diana Spencer. Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments for patients. The stories cover the efforts by research teams to… Read More

#News

Natural killer cells
#Cancer research #Icahn School of Medicine #Lung cancer #Macrophages #Oncology #Preclinical investigations

Macrophages suppress natural killer cells in lung cancer tumours

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells. “Our… Read More

#Cancer Research #News

Lung cancer
#AACR 2023 #Cancer research #Cancer treatment #Lung cancer #Oncology #Phase III trial

Therapy represents ‘new treatment paradigm’ for lung cancer

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN… Read More

#Cancer Research #News #Trending News

Non-small cell lung cancer
#Cancer research #Janssen #Lung cancer #Oncology #Trial data

Drug shows long-term response in aggressive lung cancer

New data has revealed a long-term response in patients with advanced non-small cell lung cancer (NSCLC) taking Rybrevant (amivantamab). The CHRYSALIS study is evaluating amivantamab in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease… Read More

#Cancer Research #News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

The DDW Highlights Podcast: World Cancer Day 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As 4 February was World Cancer Day, this week’s update focused on… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

This week in drug discovery (30 January – 3 February)

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will … Read More

#News